Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
Sefrioui D, Perdrix A, Sarafan-Vasseur N, Dolfus C, Dujon A, Picquenot JM, Delacour J, Cornic M, Bohers E, Leheurteur M, Rigal O, Tennevet I, Thery JC, Alexandru C, Guillemet C, Moldovan C, Veyret C, Frebourg T, Di Fiore F, Clatot F. Sefrioui D, et al. Among authors: alexandru c. Int J Cancer. 2015 Nov 15;137(10):2513-9. doi: 10.1002/ijc.29612. Epub 2015 Jun 11. Int J Cancer. 2015. PMID: 25994408
Port catheter versus peripherally inserted central catheter for postoperative chemotherapy in early breast cancer: a retrospective analysis of 448 patients.
Lefebvre L, Noyon E, Georgescu D, Proust V, Alexandru C, Leheurteur M, Thery JC, Savary L, Rigal O, Di Fiore F, Veyret C, Clatot F. Lefebvre L, et al. Among authors: alexandru c. Support Care Cancer. 2016 Mar;24(3):1397-403. doi: 10.1007/s00520-015-2901-8. Epub 2015 Sep 5. Support Care Cancer. 2016. PMID: 26342484
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.
Clatot F, Perdrix A, Augusto L, Beaussire L, Delacour J, Calbrix C, Sefrioui D, Viailly PJ, Bubenheim M, Moldovan C, Alexandru C, Tennevet I, Rigal O, Guillemet C, Leheurteur M, Gouérant S, Petrau C, Théry JC, Picquenot JM, Veyret C, Frébourg T, Jardin F, Sarafan-Vasseur N, Di Fiore F. Clatot F, et al. Among authors: alexandru c. Oncotarget. 2016 Nov 15;7(46):74448-74459. doi: 10.18632/oncotarget.12950. Oncotarget. 2016. PMID: 27801670 Free PMC article.
Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients.
Fontanilles M, Marguet F, Alexandru C, Langlois O, Veresezan O, Gilard V, David M, Laquerriere A, Hanzen C, Tennevet I, Di Fiore F, Clatot F. Fontanilles M, et al. Among authors: alexandru c. Support Care Cancer. 2019 Feb;27(2):477-484. doi: 10.1007/s00520-018-4336-5. Epub 2018 Jul 5. Support Care Cancer. 2019. PMID: 29978325
Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer.
Clatot F, Fontanilles M, Lefebvre L, Lequesne J, Veyret C, Alexandru C, Leheurteur M, Guillemet C, Gouérant S, Petrau C, Théry JC, Rigal O, Moldovan C, Tennevet I, Rastelli O, Poullain A, Savary L, Bubenheim M, Georgescu D, Gouérant J, Gilles-Baray M, Di Fiore F. Clatot F, et al. Among authors: alexandru c. Eur J Cancer. 2020 Feb;126:116-124. doi: 10.1016/j.ejca.2019.11.022. Epub 2020 Jan 10. Eur J Cancer. 2020. PMID: 31931269 Clinical Trial.
Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma.
Fontanilles M, Fontanilles A, Massy N, Rouvet J, Pereira T, Alexandru C, Hanzen C, Basuyau F, Langlois O, Clatot F, Tennevet I, Di Fiore F, Joannidès R, Lamoureux F. Fontanilles M, et al. Among authors: alexandru c. Fundam Clin Pharmacol. 2020 Aug;34(4):484-494. doi: 10.1111/fcp.12539. Epub 2020 Feb 14. Fundam Clin Pharmacol. 2020. PMID: 31994757
Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Fontanilles M, Marguet F, Ruminy P, Basset C, Noel A, Beaussire L, Viennot M, Viailly PJ, Cassinari K, Chambon P, Richard D, Alexandru C, Tennevet I, Langlois O, Di Fiore F, Laquerrière A, Clatot F, Sarafan-Vasseur N. Fontanilles M, et al. Among authors: alexandru c. Acta Neuropathol Commun. 2020 Apr 17;8(1):52. doi: 10.1186/s40478-020-00917-6. Acta Neuropathol Commun. 2020. PMID: 32303258 Free PMC article. Clinical Trial.
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
Clatot F, Perdrix A, Beaussire L, Lequesne J, Lévy C, Emile G, Bubenheim M, Lacaille S, Calbrix C, Augusto L, Guillemet C, Alexandru C, Fontanilles M, Sefrioui D, Burel L, Guénot S, Richard D, Sarafan-Vasseur N, Di Fiore F. Clatot F, et al. Among authors: alexandru c. Breast Cancer Res. 2020 May 28;22(1):56. doi: 10.1186/s13058-020-01290-x. Breast Cancer Res. 2020. PMID: 32466779 Free PMC article.
Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma.
Fontanilles M, Marguet F, Beaussire L, Magne N, Pépin LF, Alexandru C, Tennevet I, Hanzen C, Langlois O, Jardin F, Laquerrière A, Sarafan-Vasseur N, Di Fiore F, Clatot F. Fontanilles M, et al. Among authors: alexandru c. Acta Neuropathol Commun. 2020 Nov 4;8(1):179. doi: 10.1186/s40478-020-01057-7. Acta Neuropathol Commun. 2020. PMID: 33148330 Free PMC article.
Usefulness of circulating tumor DNA from cerebrospinal fluid in recurrent high-grade glioma.
Fontanilles M, Deniel A, Marguet F, Beaussire L, Magne N, Derrey S, Blanchard F, Alexandru C, Coutant S, Laquerrière A, Clatot F, Di Fiore F, Sarafan-Vasseur N. Fontanilles M, et al. Among authors: alexandru c. Rev Neurol (Paris). 2022 Nov;178(9):975-980. doi: 10.1016/j.neurol.2022.02.462. Epub 2022 Jul 21. Rev Neurol (Paris). 2022. PMID: 35871016
51 results